- Policy
- Betmiga PR prices fluctuated 3 times Between 15 days
- by Kim, Jung-Ju Nov 24, 2021 05:53am
- It is a drug with a lot of stories. Betmiga PR (Mirabegron) of Astellas Pharmaceutical of Korea, which is in a lawsuit with the government to cancel the drug price drop, is a drug with a lot of price fluctuations. The drug has repeatedly filed lawsuits against the government's drug price cut, returning, cutting and raising drug prices as t
- Policy
- MFDS cautious on waiving bridging trial for abortion pill
- by Choi-sun Nov 24, 2021 05:53am
- The Ministry of Food and Drug Safety, which had been accelerating the approval of the induced abortion pill Mifegymiso (misoprosto + mifepristone), has taken a step back in response to the caution urged by the National Assembly among others at the NA audit. Despite being advised to waiver the bridging study by the Central Pharmaceutical Affai
- Policy
- Nam In-soon's drug price recovery bill excludes rebates
- by Lee, Jeong-Hwan Nov 23, 2021 05:55am
- The "Return and refund of suspension of execution of drug prices" bill proposed by Rep. Nam In-soon of the Democratic Party of Korea varies in scope of application to benefits deletion, suspension of benefits, and drug price reduction due to revaluation of starting drugs. However, Rep. Nam In-soon's bill does not include the disposition of dr
- Company
- Bavencio cost support provided in non-reimbursed areas
- by Eo, Yun-Ho Nov 23, 2021 05:54am
- Pharmaceutical expense support for the cancer immunotherapy drug ‘Bavencio’ in non-reimbursed areas has begun. According to industry sources, Merck and Pfizer have started a patient support program to refund part of the expenses patients spend on Bavencio (avelumab) as first-line monotherapy for metastatic Merkel cell carcinoma and as f
- Company
- Myungin signed an exclusive license agreement for Parkinson
- by Nov 23, 2021 05:54am
- Myungin announced on the 22nd that it has signed a license and investment contract with Israeli pharmaceutical company Pharma Two B (P2B) for commercialization of Parkinson's disease treatment in Korea. P2B001, which is being developed by P2B, is a new combination of low-dose sustained-release drug Rasagilin and sustained-release drug Pram
- Company
- Maven Clad can be prescribed in Big 5
- by Eo, Yun-Ho Nov 23, 2021 05:54am
- Maven Clad, a new drug for multiple sclerosis, has completed its entry into the Big 5 Advanced General Hospitals. According to related industries, Merck's highly active multiple sclerosis treatment Maven Clad (Cladribine) has currently passed DC of medical institutions such as Samsung Medical Center, Seoul National University Hospital, Se
- Policy
- Brilinta’s price cut 30%, Nexavar’s premium stays 1 year
- by Kim, Jung-Ju Nov 23, 2021 05:54am
- The insurance price of AstraZeneca Korea’s Brilinta tab. 90mg (ticagrelor) and Daxas tab. 500μg (roflumilast) will be reduced by 30% through the government’s ex-officio adjustment starting next month. On the other hand, the price of Bayer Korea’s Nexavar 200mg (sorafenib tosylate) will be maintained at its level for one more year. The pri
- Policy
- Benefit for 46 generics for Eliquis will be kicked out
- by Kim, Jung-Ju Nov 22, 2021 05:52am
- BMS won the patent dispute between BMS' Eliquis (Apixaban) and it's generics, which had a patent dispute between companies due to generics released before the patent expired. Dozens of generics have been forced to withdraw their benefits. Generics will be legally removed from the list immediately on the 1st of next month due to the establishment
- Policy
- Lixiana latecomers apply for approval as an ODT
- by Lee, Tak-Sun Nov 22, 2021 05:52am
- Latecomers of Daiichi Sankyo’s novel oral anti-coagulant (NOAC) ‘Lixiana (edoxaban tosylate hydrate)’ were found to have applied for approval to the Ministry of Food and Drug Safety. Although Lixiana’s substance patent does not expire until November 10th, 2026, with the PMS (post-marketing surveillance on new drugs) period expiring on
- Company
- Prolonged delay in GSK vaccine supply may cost ₩30 bil
- by Nov 22, 2021 05:52am
- The discontinuation in the supply of many GSK vaccines is causing greater ripples. With the rising possibility that the situation may be prolonged, concerns continue over the sales gap, and procurement of substitutes is rising. GSK had announced the supply setbacks of 9 of its vaccines to primary clinics and hospitals on the 25th. The va
